Abstract
Introduction: Psoriasis is a chronic inflammatory systemic disease accompanied by systemic damage that leads to the development of multiple comorbidities including metabolic syndrome. Conventional systemic therapies for psoriasis are associated with toxicity and have a greater burden on the patients. The study aimed to assess the effectiveness of etanercept (ETN) monotherapy in comparison with methotrexate (MTX) monotherapy. Methods: In this prospective interventional comparative open-label study, 117 patients with psoriasis were randomized to 2 groups; 1 group of 42 patients; 32 (67.2%) males and 10 (23.8%) females treated with MTX, and the second group of 75 patients; 54 (72%) males and 21 (28%) females treated with ETN. Full laboratory investigations, body mass index (BMI), measurement of skin disease severity which was performed using Psoriasis Area Severity Index (PASI), and the reduction of 75% of the skin lesions (PASI 75) were calculated for all participants. Results: In the MTX group, there were no significant differences in BMI, or blood pressure after 12 weeks of the study. There is a reduction in the values of FBS, TSC, LDL, TRIG, ESR, CRP, and PASI, but this reduction was statistically not significant. Ten (23.8%) patients achieved PASI 75. In the ETN group, except for BMI, systolic and diastolic blood pressure, all other metabolic syndrome components, inflammatory markers, and PASI were decreased; the reduction was statistically significant. Sixty (80%) patients achieved PASI 75. Conclusion: Etanercept monotherapy showed greater efficacy than MTX monotherapy in the treatment of moderate to severe plaque-type psoriasis as it achieved greater reductions in PASI score and greater achievement of PASI 75 after 12 weeks. Etanercept monotherapy showed greater efficacy than MTX monotherapy in the improvement of all components of the associated metabolic syndrome except for BMI, which was increased in etanercept-treated patients.
Journal Section:
Research Article
References
1.
Azfar
RS
, Gelfand
JM
. Psoriasis and metabolic disease: epidemiology and pathophysiology
. Curr Opin Rheumatol
. 2008
;20
(4
):416
–22
. 2.
Takahashi
H
, Iizuka
H
. Psoriasis and metabolic syndrome
. J Dermatol
. 2012
;39
(3
):212
–8
. 3.
Ni
X
, Lai
Y
. Keratinocyte: a trigger or an executor of psoriasis
. J Leukoc Biol
. 2020
;108
(2
):485
–91
. 4.
Rendon
A
, Schäkel
K
. Psoriasis pathogenesis and treatment
. Int J Mol Sci
. 2019
;20
(6
):1475
. 5.
Gelfand
JM
, Neimann
AL
, Shin
DB
, Wang
X
, Margolis
DJ
, Troxel
AB
. Risk of myocardial infarction in patients with psoriasis
. JAMA
. 2006
;296
(14
):1735
–41
. 6.
Lai
YC
, Yew
YW
. Psoriasis as an independent risk factor for cardiovascular disease: an epidemiologic analysis using a national database
. J Cutan Med Surg
. 2016
;20
(4
):327
–33
. 7.
Mansouri
B
, Kivelevitch
D
, Natarajan
B
, Joshi
AA
, Ryan
C
, Benjegerdes
K
, et al. Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes
. JAMA Dermatol
. 2016
;152
(11
):1244
–53
. 8.
Mallbris
L
, Akre
O
, Granath
F
, Yin
L
, Lindelöf
B
, Ekbom
A
, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients
. Eur J Epidemiol
. 2004
;19
(3
):225
–30
. 9.
Gelfand
JM
, Troxel
AB
, Lewis
JD
, Kurd
SK
, Shin
DB
, Wang
X
, et al. The risk of mortality in patients with psoriasis: results from a population-based study
. Arch Dermatol
. 2007
;143
(12
):1493
–9
. 10.
Armstrong
AW
, Harskamp
CT
, Armstrong
EJ
. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies
. J Am Acad Dermatol
. 2013
;68
(4
):654
–62
. 11.
Madanagobalane
S
, Anandan
S
. Prevalence of metabolic syndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: a hospital-based case-control study
. Indian J Dermatol
. 2012
;57
(5
):353
–7
. 12.
Kim
GW
, Park
HJ
, Kim
HS
, Kim
SH
, Ko
HC
, Kim
BS
, et al. Analysis of cardiovascular risk factors and metabolic syndrome in Korean patients with psoriasis
. Ann Dermatol
. 2012
;24
(1
):11
–5
. 13.
Chan
JR
, Blumenschein
W
, Murphy
E
, Diveu
C
, Wiekowski
M
, Abbondanzo
S
, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis
. J Exp Med
. 2006
;203
(12
):2577
–87
. 14.
Eckel
RH
, Grundy
SM
, Zimmet
PZ
. The metabolic syndrome
. Lancet
. 2005
;365
(9468
):1415
–28
. 15.
Alberti
KG
, Zimmet
P
, Shaw
J
. Metabolic syndrome: a new world-wide definition. A consensus statement from the international diabetes federation
. Diabet Med
. 2006
;23
(5
):469
–80
. 16.
Laaksonen
DE
, Lakka
HM
, Niskanen
LK
, Kaplan
GA
, Salonen
JT
, Lakka
TA
. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study
. Am J Epidemiol
. 2002
;156
(11
):1070
–7
. 17.
Christophers
E
. Comorbidities in psoriasis
. Clin Dermatol
. 2007
;25
(6
):529
–34
. 18.
Cohen
AD
, Gilutz
H
, Henkin
Y
, Zahger
D
, Shapiro
J
, Bonneh
DY
, et al. Psoriasis and the metabolic syndrome
. Acta Derm Venereol
. 2007
;87
(6
):506
–9
. 19.
Ramamoorthy
A
, Pacanowski
MA
, Bull
J
, Zhang
L
. Racial/ethnic differences in drug disposition and response: review of recently approved drugs
. Clin Pharmacol Ther
. 2015
;97
(3
):263
–73
. 20.
Griffiths
CE
, Clark
CM
, Chalmers
RJ
, Po
AL
, Williams
HC
. A systematic review of treatments for severe psoriasis
. Health Technol Assess
. 2000
;4
(40
):1
–25
. 21.
Heydendael
VM
, Spuls
PI
, Opmeer
BC
, de Borgie
CA
, Reitsma
JB
, Goldschmidt
WF
, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
. N Engl J Med
. 2003
;349
(7
):658
–65
. 22.
Feldman
SR
, Krueger
G
. Psoriasis assessment tools in clinical trials
. Ann Rheum Dis
. 2005
;64
(Suppl 2
):ii65
–73
. 23.
Ford
ES
, Giles
WH
, Dietz
WH
. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey
. JAMA
. 2002
;287
(3
):356
–9
. 24.
Pengpid
S
, Peltzer
K
. Prevalence and associated factors of metabolic syndrome among a national population-based sample of 18–108-year-olds in Iraq: results of the 2015 STEPS survey
. Int J Diabetes Dev Ctries
. 2021
;41
(3
):427
–34
. 25.
Eckel
RH
, Alberti
KG
, Grundy
SM
, Zimmet
PZ
. The metabolic syndrome
. Lancet
. 2010
;375
(9710
):181
–3
. 26.
Henseler
T
, Christophers
E
. Disease concomitance in psoriasis
. J Am Acad Dermatol
. 1995
;32
(6
):982
–6
. 27.
Shapiro
J
, Cohen
AD
, Weitzman
D
, Tal
R
, David
M
. Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis
. J Am Acad Dermatol
. 2012
;66
(2
):252
–8
. 28.
Parodi
A
, Aste
N
, Calvieri
C
, Cantoresi
F
, Carlesimo
M
, Fabbri
P
, et al. Metabolic syndrome prevalence in psoriasis: a cross-sectional study in the Italian population
. Am J Clin Dermatol
. 2014
;15
(4
):371
–7
. 29.
Budu-Aggrey
A
, Brumpton
B
, Tyrrell
J
, Watkins
S
, Modalsli
EH
, Celis-Morales
C
, et al. Evidence of a causal relationship between body mass index and psoriasis: a mendelian randomization study
. PLoS Med
. 2019
;16
(1
):e1002739
. 30.
Briot
K
, Garnero
P
, Le Henanff
A
, Dougados
M
, Roux
C
. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment
. Ann Rheum Dis
. 2005
;64
(8
):1137
–40
. 31.
Esposito
M
, Mazzotta
A
, Saraceno
R
, Schipani
C
, Chimenti
S
. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis
. Int J Immunopathol Pharmacol
. 2009
;22
(1
):219
–25
. 32.
Owczarczyk-Saczonek
A
, Placek
W
, Rybak-d’Obyrn
J
, Wygonowska
E
. Influence of ustekinumab on body weight of patients with psoriasis: an initial report
. Postepy Dermatol Alergol
. 2014
;31
(1
):29
–31
. 33.
Plata-Salaman
CR
. Cytokines and feeding
. Physiology
. 1998
;13
(6
):298
–304
. 34.
Bach
E
, Nielsen
RR
, Vendelbo
MH
, Møller
AB
, Jessen
N
, Buhl
M
, et al. Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo-controlled, bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown, and increased IL-6 release
. Diabetes
. 2013
;62
(12
):4023
–9
. 35.
Wu
MY
, Yu
CL
, Yang
SJ
, Chi
CC
. Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis
. J Am Acad Dermatol
. 2020
;82
(1
):101
–9
. 36.
Boulton
JG
, Bourne
JT
. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis
. Rheumatology
. 2007
;46
(1
):178
–9
. 37.
Bonilla
E
, Lee
YY
, Phillips
PE
, Perl
A
. Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus
. Ann Rheum Dis
. 2007
;66
(12
):1688
. 38.
Martínez-Abundis
E
, Reynoso-von Drateln
C
, Hernández-Salazar
E
, González-Ortiz
M
. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus
. Arch Dermatol Res
. 2007
;299
(9
):461
–5
. 39.
Gisondi
P
, Cotena
C
, Tessari
G
, Girolomoni
G
. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study
. J Eur Acad Dermatol Venereol
. 2008
;22
(3
):341
–4
. 40.
Marra
M
, Campanati
A
, Testa
R
, Sirolla
C
, Bonfigli
AR
, Franceschi
C
, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis
. Int J Immunopathol Pharmacol
. 2007
;20
(4
):731
–6
. 41.
Saraceno
R
, Schipani
C
, Mazzotta
A
, Esposito
M
, Di Renzo
L
, De Lorenzo
A
, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis
. Pharmacol Res
. 2008
;57
(4
):290
–5
. 42.
Malik
S
, Wong
ND
, Franklin
S
, Pio
J
, Fairchild
C
, Chen
R
. Cardiovascular disease in US patients with metabolic syndrome, diabetes, and elevated C-reactive protein
. Diabetes Care
. 2005
;28
(3
):690
–3
. 43.
Brandt
J
, Khariouzov
A
, Listing
J
, Haibel
H
, Sörensen
H
, Grassnickel
L
, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
. Arthritis Rheum
. 2003
;48
(6
):1667
–75
. 44.
Anandarajah
AP
, Ritchlin
CT
. Etanercept in psoriatic arthritis
. Expert Opin Biol Ther
. 2003
;3
(1
):169
–77
. 45.
Hürlimann
D
, Forster
A
, Noll
G
, Enseleit
F
, Chenevard
R
, Distler
O
, et al. Anti–tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis
. Circulation
. 2002
;106
(17
):2184
–7
. 46.
Leonardi
CL
, Powers
JL
, Matheson
RT
, Goffe
BS
, Zitnik
R
, Wang
A
, et al. Etanercept as monotherapy in patients with psoriasis
. N Engl J Med
. 2003
;349
(21
):2014
–22
. 47.
Elewski
BE
, Boh
E
, Papp
K
, Zitnik
R
. Efficacy and safety of etanercept in patients with psoriasis: results of a global phase III study
. J Am Acad Dermatol
. 2004
;50
(3
):P159
. 48.
Al-Turfy
I
, Hamza
SA
. Efficacy of etanercept treatment in Iraqi patients with moderate to severe psoriasis
. Iraqi Postgrad
.49.
Obeed
RK
. Comparison of etanercept and methotrexate in the treatment of psoriasis
. Iraqi Board for Medical Specialization in dermatology and venereology
; 2018
. A thesis submitted to scientific council of dermatology and venereology.50.
Nestle
FO
, Kaplan
DH
, Barker
J
. Psoriasis
. N Engl J Med
. 2009
;361
(5
):496
–509
. 51.
Iwakura
Y
, Ishigame
H
. The IL-23/IL-17 axis in inflammation
. J Clin Invest
. 2006
;116
(5
):1218
–22
. 52.
You
T
, Yang
R
, Lyles
MF
, Gong
D
, Nicklas
BJ
. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors
. Am J Physiol Endocrinol Metab
. 2005
;288
(4
):E741
–7
. 53.
Mosca
M
, Hong
J
, Hadeler
E
, Hakimi
M
, Brownstone
N
, Liao
W
, et al. Psoriasis and cardiometabolic comorbidities: an evaluation of the impact of systemic treatments in randomized clinical trials
. Dermatol Ther
. 2021
;11
(5
):1497
–520
. 54.
UKHSA. World Health Organization (WHO)
. Estimates of tuberculosis incidence by country
; 2020
.© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
